The use of metformin in the management of polycystic ovary syndrome and associated anovulatory infertility: the current evidence
Abstract
Women suffering from anovulatory infertility are frequently diagnosed with polycystic ovary syndrome (PCOS), which is a varied condition of ovarian dysfunction characterised by hyperandrogenaemia and abnormal ovarian morphology. PCOS has been associated with insulin resistance, leading to the insulin-sensitising agent, metformin, being investigated as a useful therapy for the reinstatement of normal ovarian function and regular ovulation. While some trials and meta-analyses have produced very positive results with regard to improved ovulation rates in PCOS patients, this trend has not been universal and there has been some criticism of the acceptance of metformin as a first-line agent for PCOS. It is possible that metformin is more effective in certain patients, a hypothesis supported by the heterogeneous nature of the condition. This paper provides an overview of PCOS, reviews relevant literature regarding metformin and PCOS related infertility and discusses patient selection prior to instigating treatment.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.